Lp(a): The Inherited Heart Risk Most People Have Never Measured
AI Overview
Lipoprotein(a), usually written as Lp(a), is a cholesterol-carrying particle whose level is determined largely by genetics. Approximately one in five people has an elevated level. High Lp(a) can increase the likelihood of atherosclerotic cardiovascular disease, heart attack, stroke and calcific aortic valve disease, but it is not a diagnosis or a prediction that an event will occur. The 2026 ACC/AHA dyslipidemia guideline recommends measuring Lp(a) at least once in adulthood. An elevated result should be interpreted alongside apoB, LDL cholesterol, blood pressure, diabetes, smoking history, family history and evidence of plaque. There is not yet an approved medication specifically proven to reduce cardiovascular events by lowering Lp(a), although several targeted therapies are in advanced clinical trials. For now, the practical response is not resignation. It is more deliberate management of the cardiovascular risks that can be changed.
The One-Minute Read
Lp(a) has recently entered mainstream cardiovascular conversation, often accompanied by the claim that “one in five people carries a genetic risk for heart attack and stroke.” That wording overstates what the number means.
Approximately one in five people has an elevated Lp(a) level. The level is largely inherited and usually remains fairly stable throughout life. Elevated Lp(a) is associated with greater cardiovascular risk, but it does not mean one in five people is destined to have a heart attack or stroke. Risk still depends on the larger picture: apoB and LDL exposure, blood pressure, diabetes, smoking, family history and whether plaque is already present.
The 2026 ACC/AHA dyslipidemia guideline recommends that Lp(a) be measured at least once in adulthood. Most people will not find it on a routine lipid panel unless it is specifically ordered.
There are promising Lp(a)-lowering drugs in clinical trials, but the important outcome is not simply whether a medication lowers the laboratory number. It must also reduce heart attacks, strokes and other cardiovascular events. Until those results are established, knowing your Lp(a) can still help determine how seriously the rest of your preventable cardiovascular risk should be managed.
One in five does not mean one in five will have a heart attack
There is an important medical message underneath the recent attention surrounding lipoprotein(a). Unfortunately, it is often packaged in language that makes a risk factor sound like a genetic verdict.
About one in five people worldwide has an elevated Lp(a) level. That is not the same as saying one in five people carries a genetic condition that will cause a heart attack or stroke.
Lp(a) is a risk-enhancing factor. It can raise cardiovascular risk, sometimes substantially, but it does not operate alone. A person’s future risk still reflects decades of exposure to apoB-containing particles, blood pressure, glucose regulation, smoking, inflammation, family history and existing arterial plaque.
The distinction is not an argument against testing. It is the reason testing should be interpreted carefully.
What is Lp(a)?
Lp(a), pronounced “L-P-little-a,” resembles an LDL particle. It contains apolipoprotein B, or apoB, with an additional protein called apolipoprotein(a) attached to it.
Like LDL particles, Lp(a) can contribute to cholesterol deposition within the artery wall. Its structure may also contribute to inflammation, thrombosis and calcification. Elevated levels are associated with atherosclerotic cardiovascular disease and calcific aortic valve stenosis.
Your Lp(a) concentration is controlled primarily by variations in the LPA gene. Diet and exercise remain important for overall cardiovascular health, but they generally have little effect on the Lp(a) number itself.
That can be frustrating to hear. It can also be clarifying. A high result is not evidence that you ate incorrectly or failed to exercise enough.
Why most people have never measured it
A standard cholesterol panel usually reports total cholesterol, LDL cholesterol, HDL cholesterol and triglycerides. Lp(a) is a separate test and may not be included unless a clinician orders it specifically.
The 2026 ACC/AHA dyslipidemia guideline now recommends measuring Lp(a) at least once in adulthood. Because levels are largely inherited and relatively stable, repeated measurement is generally unnecessary for most people unless there is a specific clinical reason to retest.
This represents a meaningful change in cardiovascular prevention. Previously, testing was often reserved for people with premature cardiovascular disease, a strong family history, familial hypercholesterolemia or cardiovascular events that seemed disproportionate to their traditional risk factors.
Those groups still have compelling reasons to know their level. The difference is that testing is no longer limited to them.
What counts as elevated?
Lp(a) may be reported in either milligrams per deciliter or nanomoles per liter. These units measure different properties and cannot be converted reliably with one universal formula.
The 2026 ACC/AHA guideline identifies an Lp(a) level of at least 125 nmol/L, or approximately 50 mg/dL, as a cardiovascular risk-enhancing factor. At that level, estimated long-term risk of heart attack or stroke is approximately 1.4 times higher. Levels around 250 nmol/L, or 100 mg/dL, are associated with at least twice the estimated risk.
These are population-level estimates. They do not tell one individual exactly what will happen.
A result of 150 nmol/L means something different in a healthy nonsmoker with optimal blood pressure, low apoB and no detectable plaque than it does in someone with diabetes, hypertension, elevated apoB and established coronary disease.
Lp(a) is not just another form of LDL cholesterol
Lp(a) and LDL are related, but they are not interchangeable.
A person can have an acceptable LDL cholesterol result and still have elevated Lp(a). Conversely, someone can have high LDL with a normal Lp(a). Some people have both, increasing their cumulative burden of apoB-containing particles.
There is another laboratory complication. Cholesterol carried within Lp(a) is included in the reported LDL cholesterol measurement. When Lp(a) is very high, part of what appears to be LDL cholesterol may actually be cholesterol contained inside Lp(a) particles.
This is one reason we prefer to look beyond a single LDL cholesterol result. ApoB measures the number of atherogenic particles more directly and can provide useful additional context.
Read more about ApoB testing and cardiovascular risk.
There is no approved Lp(a)-specific outcomes treatment yet
This is where some of the excitement moves ahead of the evidence.
Several RNA-targeted medications—including pelacarsen, olpasiran and lepodisiran—have produced large reductions in Lp(a) in clinical studies. That is scientifically promising.
Lowering a laboratory value, however, is not the final clinical standard. Researchers must show that lowering Lp(a) also prevents heart attacks, strokes, cardiovascular deaths or other meaningful events. Large cardiovascular outcomes trials are evaluating that question.
Until those results are available and the therapies are approved, “treatments are on the horizon” is reasonable language. “We can now treat elevated Lp(a)” would be premature.
PCSK9 inhibitors can reduce Lp(a) modestly while producing much larger reductions in LDL cholesterol. Lipoprotein apheresis may be used in selected patients with severe disease, but it is not a practical treatment for the broader population with elevated Lp(a). Niacin can lower the number, but it has not established a cardiovascular benefit that justifies using it solely for elevated Lp(a), and side effects are common.
What can be done now?
You cannot choose the Lp(a) level you inherited. You can still change the environment in which that risk operates.
The presence of elevated Lp(a) should prompt a more careful review of modifiable cardiovascular risk. That may include:
- Lowering LDL cholesterol and apoB more aggressively when appropriate
- Managing blood pressure
- Addressing insulin resistance and diabetes
- Avoiding smoking
- Maintaining regular aerobic activity and strength training
- Following a Plant- and Protein-Forward Mediterranean Diet
- Evaluating family history of premature cardiovascular disease
- Determining whether arterial plaque is already present when the answer would change treatment
For some people, the Lp(a) result will not substantially change the plan. Their apoB, blood pressure and other risks already require attention. For others, it may help explain premature disease, strengthen the case for more intensive prevention or support additional plaque assessment.
Should everyone with high Lp(a) get a coronary CT angiogram?
No.
An elevated Lp(a) result is not an automatic indication for coronary CT angiography, Cleerly analysis or another imaging study. Testing should answer a clinical question and have a reasonable chance of changing management.
Age, symptoms, family history, apoB, blood pressure, diabetes, previous calcium scoring and the degree of Lp(a) elevation all affect that decision.
A coronary artery calcium score may be useful in some asymptomatic adults. Coronary CT angiography provides different information, including visualization of calcified and noncalcified plaque, but involves contrast and radiation and should not be ordered simply because one risk marker is elevated.
Carotid intima-media thickness and plaque assessment can also contribute information about vascular health in selected patients. No single scan replaces clinical judgment.
Compare the HormoneSynergy Optimal Aging Assessment with Cleerly testing.
Family testing may matter
Because Lp(a) is strongly inherited, an elevated result can be relevant to first-degree relatives. Parents, siblings and adult children may also benefit from testing.
This is sometimes called cascade screening. It does not mean every relative will have the same level, but it can identify risk earlier—before cardiovascular disease becomes the reason anyone thinks to look.
The HormoneSynergy perspective
Lp(a) deserves a place in modern cardiovascular prevention. It should have had one sooner.
It should not, however, be turned into another frightening number presented without context. An elevated result is neither harmless nor destiny. It is one piece of a broader risk assessment.
The most useful response is to measure it once, interpret it alongside the rest of the cardiovascular picture and decide whether it changes what should be done now.
Future therapies may give us a way to lower Lp(a) directly. Until then, prevention still depends on disciplined attention to apoB, blood pressure, metabolic health, smoking, fitness and the presence or absence of plaque.
Genetics may load part of the cardiovascular risk. It does not write the entire outcome.
Preventive cardiovascular assessment at HormoneSynergy
HormoneSynergy evaluates Lp(a) in the context of apoB, advanced lipids, blood pressure, metabolic health, family history, vascular testing and other individualized risk factors. Testing should lead to a prevention strategy—not simply another abnormal result in a patient portal.
Frequently Asked Questions
What is Lp(a)?
Lp(a) is an apoB-containing cholesterol particle with an additional protein called apolipoprotein(a). Its level is determined primarily by genetics, and elevated levels are associated with greater risk of atherosclerotic cardiovascular disease, stroke and calcific aortic valve stenosis.
Is Lp(a) included in a routine cholesterol panel?
Usually not. It generally must be ordered as a separate blood test.
How often should Lp(a) be tested?
The 2026 ACC/AHA dyslipidemia guideline recommends measuring it at least once in adulthood. Because it is largely genetically determined and relatively stable, one measurement is sufficient for most people.
What Lp(a) level is considered high?
A level of at least 125 nmol/L or 50 mg/dL is generally considered a cardiovascular risk-enhancing level. The two units are not directly interchangeable with a single reliable conversion formula.
Can diet and exercise lower Lp(a)?
They usually have little effect on the Lp(a) number itself. They remain important because they can improve many of the other factors that determine total cardiovascular risk.
Are medications available specifically for elevated Lp(a)?
Several targeted medications are in advanced clinical trials, but there is not yet an approved medication specifically proven to reduce cardiovascular events by lowering Lp(a). Existing therapies may be used to reduce the person’s overall cardiovascular risk.
Does elevated Lp(a) mean I need a heart scan?
Not automatically. Imaging decisions should depend on age, symptoms, family history, other risk factors and whether the result would change treatment.
Should family members be tested?
Because Lp(a) is inherited, first-degree relatives of someone with an elevated result may benefit from having their level measured.
References
- American College of Cardiology. ACC/AHA Issue Updated Guideline for Managing Lipids and Cholesterol. 2026.
- American Heart Association. 2026 Guideline on the Management of Dyslipidemia: Top Things to Know.
- American Heart Association. Lipoprotein(a).
- Centers for Disease Control and Prevention. About Lipoprotein(a).
- ClinicalTrials.gov. Lp(a)HORIZON: Pelacarsen Cardiovascular Outcomes Trial.
- ClinicalTrials.gov. OCEAN(a)-Outcomes: Olpasiran Cardiovascular Outcomes Trial.
- ClinicalTrials.gov. ACCLAIM-Lp(a): Lepodisiran Cardiovascular Outcomes Trial.
Editorial Transparency
This article is educational and does not replace individualized medical care. Cardiovascular testing and treatment should be based on a person’s complete health history, symptoms, medications, laboratory findings and existing evidence of vascular disease. HormoneSynergy is a private-pay Preventive Longevity Medicine clinic and does not accept Medicare, Medicaid or Tricare.
Continue exploring:
- HormoneSynergy Longevity Medicine Resource Library
- Optimal Aging Assessment
- Optimal Aging Assessment vs. Cleerly Testing
Read more about ApoB testing and cardiovascular risk.
This article is part of the HormoneSynergy® Longevity Medicine education series covering preventive cardiology, metabolic health, hormone optimization, body composition, and advanced diagnostics for healthy aging.
Return to the Longevity Medicine Guide →